“`html
RadNet (NASDAQ:RDNT), a leading outpatient diagnostic imaging services provider, reported record Q2 2025 results with total revenue increasing 8.4% to $498.2 million and Adjusted EBITDA growing 12.3% to $81.2 million. The company’s Digital Health segment saw significant growth with revenue up 30.9% to $20.7 million.
Advanced imaging volumes showed strong performance, with MRI volume up 9.0%, CT volume up 8.1%, and PET/CT volume surging 22.4%. The company achieved Adjusted Earnings of $23.8 million ($0.31 per share), compared to $12.0 million ($0.16 per share) in Q2 2024.
Based on strong performance, RadNet revised its 2025 guidance upward, with total net revenue now projected at $1.85-1.90 billion and Adjusted EBITDA expected between $271-279 million.
RadNet (NASDAQ:RDNT), fornitore leader di servizi di diagnostica per immagini in regime ambulatoriale, ha registrato risultati record nel Q2 2025 con ricavi totali in aumento dell’8,4% a $498.2 million e EBITDA rettificato in crescita del 12,3% a $81.2 million. Il segmento Digital Health ha segnato una forte crescita, con ricavi saliti del 30,9% a $20.7 million.
I volumi di diagnostica avanzata hanno mostrato ottime performance: volumi MRI in aumento del 9,0%, CT +8,1% e PET/CT in forte crescita del 22,4%. L’utile rettificato ha raggiunto $23.8 million ($0.31 per azione), rispetto a $12.0 million ($0.16 per azione) nel Q2 2024.
Sulla base di questi risultati, RadNet ha rivisto al rialzo le previsioni per il 2025: i ricavi netti totali sono ora stimati a $1.85-1.90 miliardi e l’EBITDA rettificato è previsto tra $271-279 million.
RadNet (NASDAQ:RDNT), proveedor líder de servicios de diagnóstico por imagen ambulatorio, informó resultados récord en el Q2 2025 con ingresos totales que aumentaron 8.4% hasta $498.2 million y EBITDA ajustado que creció 12.3% hasta $81.2 million. Su segmento de Digital Health experimentó un crecimiento notable, con ingresos al alza 30.9% hasta $20.7 million.
Los volúmenes de imagen avanzada mostraron un rendimiento sólido: volumen de MRI +9.0%, CT +8.1% y PET/CT +22.4%. La utilidad ajustada fue de $23.8 million ($0.31 por acción), frente a $12.0 million ($0.16 por acción) en el Q2 2024.
Tras este desempeño, RadNet elevó su guía para 2025: ahora proyecta ingresos netos totales de $1.85-1.90 mil millones y un EBITDA ajustado esperado entre $271-279 million.
RadNet (NASDAQ:RDNT), 선도적인 외래 진단 영상 서비스 제공업체가 2025년 2분기 실적에서 기록적인 성과를 발표했습니다. 총수익은 8.4% 증가한 $498.2 million, 조정 EBITDA는 12.3% 성장한 $81.2 million을 기록했습니다. 디지털 헬스(Digital Health) 부문 매출은 30.9% 증가한 $20.7 million로 큰 폭의 성장을 보였습니다.
고급 영상의 볼륨도 견조하게 증가했으며, MRI 볼륨 9.0% 증가, CT 8.1% 증가, PET/CT 22.4% 급증했습니다. 조정 순이익은 $23.8 million($0.31/주)로, 전년 동기인 Q2 2024의 $12.0 million($0.16/주)에서 증가했습니다.
이 같은 강한 실적을 바탕으로 RadNet은 2025년 가이던스를 상향 조정했습니다. 총 순매출은 $1.85-1.90 billion으로, 조정 EBITDA는 $271-279 million 사이로 예상됩니다.
RadNet (NASDAQ:RDNT), acteur majeur des services d’imagerie diagnostique en ambulatoire, a publié des résultats records pour le T2 2025 avec des revenus totaux en hausse de 8,4% à $498,2 millions et un EBITDA ajusté en progression de 12,3% à $81,2 millions. Le segment Digital Health a connu une croissance marquée, les revenus augmentant de 30,9% à $20,7 millions.
Les volumes d’imagerie avancée ont été solides : volume MRI en hausse de 9,0%, CT +8,1% et PET/CT +22,4%. Le bénéfice ajusté s’est établi à $23,8 millions ($0,31 par action), contre $12,0 millions ($0,16 par action) au T2 2024.
Au vu de ces performances, RadNet a relevé ses prévisions pour 2025 : le chiffre d’affaires net total est désormais attendu entre $1,85 et $1,90 milliard et l’EBITDA ajusté entre $271 et $279 millions.
RadNet (NASDAQ:RDNT), ein führender Anbieter ambulanter diagnostischer Bildgebungsdienstleistungen, meldete Rekordergebnisse für das Q2 2025: der Gesamtumsatz stieg um 8,4% auf $498,2 Millionen und das bereinigte EBITDA wuchs um 12,3% auf $81,2 Millionen. Das Digital-Health-Segment verzeichnete ein deutliches Wachstum mit einem Umsatzanstieg von 30,9% auf $20,7 Millionen.
Die Volumina in der erweiterten Bildgebung entwickelten sich stark: MRI-Volumen +9,0%, CT +8,1% und PET/CT +22,4%. Das bereinigte Ergebnis betrug $23,8 Millionen ($0,31 je Aktie) gegenüber $12,0 Millionen ($0,16 je Aktie) im Q2 2024.
Aufgrund der soliden Performance hat RadNet die Prognose für 2025 nach oben korrigiert: Der Gesamtumsatz wird nun bei $1,85–1,90 Milliarden und das bereinigte EBITDA zwischen $271–279 Millionen erwartet.
Upsides
- Record quarterly revenue of $498.2M, up 8.4% year-over-year
- Adjusted EBITDA margins improved by 57 basis points to 16.3%
- Digital Health segment revenue increased 30.9% to $20.7M
- Strong advanced imaging growth: MRI +9.0%, CT +8.1%, PET/CT +22.4%
- Adjusted EPS nearly doubled to $0.31 from $0.16 year-over-year
- Strong balance sheet with $833.2M cash and low leverage ratio of 0.96x
- Upward revision of 2025 financial guidance
Downsides
- $23.5M net loss for first six months of 2025, compared to $5.8M loss in 2024
- Increased R&D expenses with $4.8M in non-capitalized research costs
- $15M estimated Adjusted EBITDA loss from California wildfires and winter weather in Q1 2025
Insights
RadNet posted record Q2 results with 8.4% revenue growth and 12.3% EBITDA growth, driving upward 2025 guidance revision.
RadNet delivered exceptional Q2 2025 performance with total revenue reaching a record $498.2 million, up 8.4% year-over-year. The company’s strategic focus on advanced imaging is clearly paying dividends – these higher-margin procedures now represent 27.5% of total volume, up 102 basis points from Q2 2024.
The profit metrics are particularly impressive. Adjusted EBITDA hit a record $81.2 million, growing 12.3% year-over-year with margins expanding 57 basis points to 16.3%. This margin expansion demonstrates operational leverage and effective cost management despite ongoing expansion initiatives.
RadNet’s Digital Health segment shows promising momentum with 30.9% revenue growth to $20.7 million. While still relatively small compared to the core imaging business, this segment represents a high-growth opportunity with its AI-powered Enhanced Breast Cancer Detection program now reaching nearly half of RadNet’s mammography patients.
The company’s balance sheet strength is noteworthy with $833.2 million in cash and a low Net Debt to Adjusted EBITDA ratio of 0.96x. This strong liquidity position provides significant flexibility for continued expansion through both de novo center development and potential acquisitions.
Looking at procedural volumes, PET/CT stands out with 22.4% growth, followed by MRI at 9.0% and CT at 8.1%. The company’s investments in technology like TechLive™ (remote scanning) and focus on complex procedures are driving higher utilization and helping address technologist staffing challenges.
The upward revision of 2025 guidance for both revenue and EBITDA signals management’s confidence in continued strong performance. With nine additional de novo facilities planned for the remainder of 2025, RadNet is positioning for sustained growth while maintaining profitability.
08/10/2025 – 04:00 PM
- Total Company Revenue increased 8.4% to a quarterly record of $498.2 million in the second quarter of 2025 from $459.7 million in the second quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 30.9% to a quarterly record of $20.7 million in the second quarter of 2025 from $15.8 million in the second quarter of 2024
- Total Company Adjusted EBITDA(1) was a quarterly record of $81.2 million in the second quarter of 2025 as compared with $72.3 million in the second quarter of 2024, an increase of 12.3%; Digital Health reportable segment Adjusted EBITDA(1) increased 4.1% to $3.4 million in the second quarter of 2025 from $3.3 million in the second quarter of 2024
- Total Company Adjusted EBITDA(1) margins increased by 57 basis points to 16.3% in the second quarter of 2025 as compared with 15.7% in the second quarter of 2024
- As a percentage of total procedural volumes, advanced imaging increased to 27.5% in the second quarter of 2025 from 26.5% in the second quarter of 2024, an increase of 102 basis points
- Adjusting for unusual or one-time items in the quarter, Adjusted Earnings(3) was $23.8 million and Adjusted Earnings Per Share(3) was $0.31 for the second quarter of 2025; This compares with Adjusted Earnings(3) of $12.0 million and Adjusted Earnings Per Share(3) of $0.16 for the second quarter of 2024
- In the second quarter of 2025, aggregate advanced imaging (MRI, CT and PET/CT) procedural volumes increased 9.0% and same-center advanced imaging procedural volumes increased 6.6% as compared with the second quarter of 2024
- As of June 30, 2025, balance sheet cash was $833.2 million and Net Debt to Adjusted EBITDA(1) ratio was 0.96x
- RadNet revises full-year 2025 guidance levels to increase Revenue and Adjusted EBITDA(1) guidance ranges
LOS ANGELES, Aug. 10, 2025 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 405 owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2025.
**RadNet (RDNT) Posts Record Q2, Raises Full-Year Guidance**
**LOS ANGELES–** RadNet (RDNT) just delivered a blockbuster second quarter for 2025, exceeding expectations and prompting an upward revision of its full-year financial guidance. The outpatient diagnostic imaging powerhouse reported record quarterly revenue of $498.2 million, a healthy 8.4% jump compared to the same period last year. Even more impressive, Adjusted EBITDA surged 12.3% to $81.2 million, signaling improved operational efficiency.
“Both the Imaging Center and Digital Health reportable operating segments demonstrated strong growth and achieved record quarterly results. In the second quarter of 2025, total Company Revenue grew 8.4% and Digital Health segment Revenue increased 30.9% from last year’s same quarter,” noted Dr. Howard Berger, President and Chief Executive Officer of RadNet, in a statement. The growth was fueled by rising procedural volumes, particularly in advanced imaging, favorable reimbursement rates, and increasing contributions from its Digital Health division.
**Digital Health Shines**
RadNet’s Digital Health segment continues to be a growth engine, posting a remarkable 30.9% increase in revenue to $20.7 million. This division is leveraging AI and innovative software solutions to improve diagnostic accuracy and workflow efficiency.
**Advanced Imaging Drives Profits**
The company’s strategic focus on higher-margin advanced imaging modalities is paying off handsomely. MRI volume increased by 9.0%, CT by 8.1%, and PET/CT by a remarkable 22.4%. These advanced procedures now account for a significant 27.5% of total procedural volumes. RadNet’s investment in technologies like remote scanning are also contributing to higher utilization rates and addressing staffing challenges.
**Strong Balance Sheet, Rosy Outlook**
RadNet boasts a robust balance sheet with $833.2 million in cash and a low net debt to Adjusted EBITDA ratio of just 0.96x. This financial strength provides ample room for expansion, both organically through new center development and potentially through strategic acquisitions.
Bolstered by these strong results, RadNet is raising its full-year 2025 guidance. The company now projects total net revenue in the range of $1.85 billion to $1.90 billion and Adjusted EBITDA between $271 million and $279 million. This paints a picture of continued growth and profitability for the remainder of the year.
However, investors should note that RadNet reported a net loss of $23.5 million for the first six months of 2025, compared to a $5.8 million loss in the same period last year, partially reflecting the impact of California wildfires and severe winter weather in Q1 2025.
**Key Highlights:**
* **Record Q2 Revenue:** $498.2 million, up 8.4% year-over-year.
* **Adjusted EBITDA Surge:** Up 12.3% to $81.2 million.
* **Digital Health Growth:** Revenue up 30.9% to $20.7 million.
* **Advanced Imaging Boom:** MRI volume +9.0%, CT +8.1%, PET/CT +22.4%.
* **Profitability Increase:** Adjusted EPS nearly doubled to $0.31
* **2025 Guidance Boost:** Revenue projected at $1.85-1.90 billion, Adjusted EBITDA at 271-279 million.
Looks like RadNet is poised for continued success.
FAQ
What were RadNet’s (RDNT) key financial results for Q2 2025?
RadNet reported record quarterly revenue of $498.2M (up 8.4%) and Adjusted EBITDA of $81.2M (up 12.3%) compared to Q2 2024. Adjusted earnings per share increased to $0.31 from $0.16 year-over-year.
How did RadNet’s Digital Health segment perform in Q2 2025?
The Digital Health segment achieved revenue of $20.7M (up 30.9%) and Adjusted EBITDA of $3.4M (up 4.1%) compared to Q2 2024.
What is RadNet’s updated revenue guidance for 2025?
RadNet revised its 2025 guidance upward, projecting total net revenue between $1.85-1.90 billion, increased from the previous guidance of $1.835-1.885 billion.
How did RadNet’s advanced imaging volumes perform in Q2 2025?
Advanced imaging volumes showed strong growth with MRI up 9.0%, CT up 8.1%, and PET/CT up 22.4% compared to Q2 2024.
What is RadNet’s current financial position?
RadNet maintains a strong balance sheet with $833.2M in cash and a Net Debt to Adjusted EBITDA ratio of 0.96x as of June 30, 2025.
